A Phase 2 interventional study of BMS-986165 in Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb. Completed at 98 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb — 5 open to participants now, 9 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Bristol-Myers Squibb.
Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2019, is one of 7 in phase 2, and was the 9th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →5 of the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States
Ages 18–75
Bristol-Myers Squibb · Sites in United States, Argentina, Brazil and 10 more countries
Ages 16+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Bristol-Myers Squibb
Ages 4–75
Bristol-Myers Squibb · Sites in United States, Belgium, France and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 4 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 125 across the 19 interventional studies, 223 across the 1 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986165
Drug: BMS-986165
Drug: BMS-986165
Specified dose on specified days
Also known as: Deucravacitinib
Number of Participants With Treatment-Emergent Adverse Events and Treatment Emergent Serious Adverse Events
A Treatment-Emergent Adverse Event (TEAE) is any untoward medical occurrence that begins or worsens after the first dose of study treatment, including any unfavorable sign, symptom, disease, or abnormal lab finding, whether or not related to the product, and may include worsening of pre-existing conditions. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is considered an important medical event requiring intervention to prevent these outcomes.
Time frame: From Day 1 until 30 days after last dose (up to approximately 42 months)
Number of Participants With Abnormalities in Vital Signs
Vital signs heart rate (HR) (beats/min), systolic blood pressure (SBP) (mmHG), and diastolic blood pressure (DBP) (mmHg).
Time frame: From Day 1 until 30 days after last dose (up to approximately 42 months)
Number of Participants With Grade 3 or Grade 4 Laboratory Abnormalities
Blood samples were collected to assess laboratory parameters. Grade 3 = Severe laboratory abnormality Grade 4 = Life-threatening or very severe laboratory abnormality
Time frame: From Day 1 until 30 days after last dose (up to approximately 42 months)
| Milestone | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID |
|---|---|---|---|---|---|---|
| Started | 58 | 73 | 67 | 21 | 21 | 21 |
| Completed | 35 | 44 | 42 | 8 | 13 | 9 |
| Not completed | 23 | 29 | 25 | 13 | 8 | 12 |
| Withdrew: Other reasons | 11 | 11 | 11 | 6 | 4 | 5 |
| Withdrew: Withdrawal by subject | 3 | 6 | 4 | 5 | 2 | 2 |
| Withdrew: Site terminated by sponsor | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 4 | 1 | 0 | 2 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 7 | 4 | 2 | 0 | 3 |
A Treatment-Emergent Adverse Event (TEAE) is any untoward medical occurrence that begins or worsens after the first dose of study treatment, including any unfavorable sign, symptom, disease, or abnormal lab finding, whether or not related to the product, and may include worsening of pre-existing conditions. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is considered an important medical event requiring intervention to prevent these outcomes.
| Participants | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID |
|---|---|---|---|---|---|---|
| Treatment Emergent Adverse Events | 51 | 63 | 62 | 21 | 19 | 18 |
| Treatment Emergent Serious Adverse Events | 13 | 9 | 11 | 4 | 0 | 3 |
Vital signs heart rate (HR) (beats/min), systolic blood pressure (SBP) (mmHG), and diastolic blood pressure (DBP) (mmHg).
| Participants | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID |
|---|---|---|---|---|---|---|
| HR VALUE > 100 AND CHANGE FROM BASELINE > 30 | 2 | 1 | 1 | 0 | 1 | 1 |
| HR VALUE < 55 AND CHANGE FROM BASELINE < -15 | 0 | 0 | 0 | 0 | 0 | 0 |
| SBP VALUE > 140 AND CHANGE FROM BASELINE > 20 | 4 | 7 | 9 | 2 | 0 | 2 |
| SBP VALUE < 90 AND CHANGE FROM BASELINE < -20 | 0 | 0 | 0 | 0 | 0 | 0 |
| DBP VALUE > 90 AND CHANGE FROM BASELINE > 10 | 7 | 10 | 13 | 2 | 3 | 2 |
| DBP VALUE < 55 AND CHANGE FROM BASELINE < -10 | 0 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected to assess laboratory parameters. Grade 3 = Severe laboratory abnormality Grade 4 = Life-threatening or very severe laboratory abnormality
| Participants | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID |
|---|---|---|---|---|---|---|
| HEMOGLOBIN (G/L) GRADE 3 | 0 | 2 | 1 | 0 | 0 | 1 |
| LYMPHOCYTES (10^9/L) GRADE 3 | 3 | 3 | 10 | 2 | 0 | 3 |
| LYMPHOCYTES (10^9/L) GRADE 4 | 0 | 0 | 0 | 0 | 1 | 1 |
| NEUTROPHILS (10^9/L) GRADE 3 | 3 | 3 | 2 | 0 | 2 | 0 |
| NEUTROPHILS (10^9/L) GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| PLATELETS (10^9/L) GRADE 3 | 0 | 0 | 1 | 0 | 0 | 0 |
| PLATELETS (10^9/L) GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| LEUKOCYTES (10^9/L) GRADE 3 | 2 | 1 | 0 | 0 | 1 | 1 |
| LEUKOCYTES (10^9/L) GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALBUMIN (G/L) GRADE 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALKALINE PHOSPHATASE (IU/L) GRADE 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALKALINE PHOSPHATASE (IU/L) GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| ALANINE AMINOTRANSFERASE (U/L) GRADE 3 | 1 | 0 | 1 | 1 | 1 | 0 |
| ALANINE AMINOTRANSFERASE (U/L) GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| ASPARTATE AMINOTRANSFERASE (U/L) GRADE 3 | 1 | 0 | 1 | 1 | 0 | 0 |
| ASPARTATE AMINOTRANSFERASE (U/L) GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| BILIRUBIN (UMOL/L) GRADE 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| BILIRUBIN (UMOL/L) GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| CREATINE KINASE (IU/L) GRADE 3 | 2 | 0 | 1 | 0 | 0 | 0 |
| CREATINE KINASE (IU/L) GRADE 4 | 0 | 0 | 0 | 0 | 1 | 0 |
| CREATININE (UMOL/L) GRADE 3 | 0 | 0 | 1 | 0 | 0 | 0 |
| CREATININE (UMOL/L) GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| GAMMA GLUTAMYL TRANSFERASE (U/L) GRADE 3 | 2 | 0 | 1 | 1 | 0 | 0 |
| GAMMA GLUTAMYL TRANSFERASE (U/L) GRADE 4 | 0 | 0 | 1 | 0 | 0 | 0 |
| GLUCOSE (MMOL/L) GRADE 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| GLUCOSE (MMOL/L) GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERCALCEMIA GRADE 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERCALCEMIA GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERKALEMIA GRADE 3 | 0 | 0 | 1 | 0 | 0 | 0 |
| HYPERKALEMIA GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERMAGNESEMIA GRADE 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERMAGNESEMIA GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERNATREMIA GRADE 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPERNATREMIA GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPOCALCEMIA GRADE 3 | 1 | 1 | 1 | 0 | 0 | 0 |
| HYPOCALCEMIA GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPOKALEMIA GRADE 3 | 1 | 1 | 1 | 0 | 1 | 0 |
| HYPOKALEMIA GRADE 4 | 0 | 1 | 0 | 0 | 0 | 0 |
| HYPOMAGNESEMIA GRADE 3 | 1 | 0 | 1 | 0 | 0 | 0 |
| HYPOMAGNESEMIA GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| HYPONATREMIA GRADE 3 | 0 | 0 | 1 | 0 | 0 | 0 |
| HYPONATREMIA GRADE 4 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over All cause mortality was collected from first dose (Day 1) until study completion (up to approximately 312 weeks). AEs and SAEs were collected from first dose (Day 1) till 30 days after last dose (up to approximately 42 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DEUC 12mg QD - DEUC 12mg QD | 0/58 (0%) | 13/58 (22.4%) | 43/58 (74.1%) |
| DEUC 6mg BID - DEUC 6mg BID | 0/73 (0%) | 9/73 (12.3%) | 53/73 (72.6%) |
| DEUC 3mg BID - DEUC 3mg BID | 1/67 (1.5%) | 11/67 (16.4%) | 51/67 (76.1%) |
| PBO BID - DEUC 12mg QD | 0/21 (0%) | 4/21 (19%) | 16/21 (76.2%) |
| PBO BID - DEUC 6mg BID | 0/21 (0%) | 0/21 (0%) | 16/21 (76.2%) |
| PBO BID - DEUC 3mg BID | 0/21 (0%) | 3/21 (14.3%) | 16/21 (76.2%) |
| Event | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID |
|---|---|---|---|---|---|---|
| ColitisGastrointestinal disorders | 0/58 | 0/73 | 0/67 | 1/21 | 0/21 | 0/21 |
| Non-cardiac chest painGeneral disorders | 0/58 | 0/73 | 0/67 | 1/21 | 0/21 | 0/21 |
| AppendicitisInfections and infestations | 2/58 | 0/73 | 0/67 | 0/21 | 0/21 | 1/21 |
| Infected dermal cystInfections and infestations | 0/58 | 0/73 | 0/67 | 1/21 | 0/21 | 0/21 |
| Fracture displacementInjury, poisoning and procedural complications | 0/58 | 0/73 | 0/67 | 1/21 | 0/21 | 0/21 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/58 | 0/73 | 0/67 | 0/21 | 0/21 | 1/21 |
| Adnexa uteri cystReproductive system and breast disorders | 0/58 | 0/73 | 0/67 | 0/21 | 0/21 | 1/21 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/58 | 1/73 | 0/67 | 1/21 | 0/21 | 0/21 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 2/58 | 1/73 | 1/67 | 0/21 | 0/21 | 0/21 |
| COVID-19 pneumoniaInfections and infestations | 1/58 | 2/73 | 1/67 | 0/21 | 0/21 | 0/21 |
| Event | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 16/58 | 21/73 | 24/67 | 4/21 | 4/21 | 5/21 |
| NasopharyngitisInfections and infestations | 13/58 | 10/73 | 13/67 | 4/21 | 5/21 | 1/21 |
| Urinary tract infectionInfections and infestations | 8/58 | 16/73 | 11/67 | 3/21 | 3/21 | 3/21 |
| Upper respiratory tract infectionInfections and infestations | 11/58 | 11/73 | 13/67 | 2/21 | 2/21 | 2/21 |
| DiarrhoeaGastrointestinal disorders | 3/58 | 5/73 | 3/67 | 1/21 | 4/21 | 1/21 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/58 | 4/73 | 2/67 | 3/21 | 1/21 | 0/21 |
| PharyngitisInfections and infestations | 1/58 | 3/73 | 4/67 | 1/21 | 3/21 | 2/21 |
| HeadacheNervous system disorders | 7/58 | 5/73 | 7/67 | 3/21 | 1/21 | 2/21 |
| AcneSkin and subcutaneous tissue disorders | 3/58 | 3/73 | 1/67 | 3/21 | 2/21 | 2/21 |
| Herpes zosterInfections and infestations | 3/58 | 9/73 | 5/67 | 1/21 | 1/21 | 2/21 |
| Age, Continuous(years) | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID | Total |
|---|---|---|---|---|---|---|---|
| Mean | 38.0 ± 9.56 | 43.4 ± 11.87 | 41.1 ± 12.32 | 44.6 ± 13.39 | 41.5 ± 14.26 | 44.1 ± 12.90 | 41.6 ± 12.04 |
| Sex: Female, Male(Participants) | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID | Total |
|---|---|---|---|---|---|---|---|
| Female | 51 | 68 | 62 | 19 | 18 | 17 | 235 |
| Male | 7 | 5 | 5 | 2 | 3 | 4 | 26 |
| Ethnicity (NIH/OMB)(Participants) | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 19 | 20 | 21 | 4 | 9 | 7 | 80 |
| Not Hispanic or Latino | 39 | 53 | 46 | 17 | 11 | 14 | 180 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | DEUC 12mg QD - DEUC 12mg QD | DEUC 6mg BID - DEUC 6mg BID | DEUC 3mg BID - DEUC 3mg BID | PBO BID - DEUC 12mg QD | PBO BID - DEUC 6mg BID | PBO BID - DEUC 3mg BID | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 4 | 3 | 1 | 1 | 1 | 12 |
| Asian | 7 | 13 | 7 | 5 | 3 | 2 | 37 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 5 | 7 | 2 | 0 | 1 | 21 |
| White | 36 | 44 | 43 | 12 | 14 | 15 | 164 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others | 7 | 7 | 7 | 1 | 3 | 2 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2019 to primary completion in Mar 2025, 71 months.
Results were first posted in Mar 2026, 11 months after primary completion.
Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 71 months is above that.
Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib
Lupus Erythematosus, Systemic →